文献速递临床试验与 GCP流行病学与生物统计

初级保健中偏头痛一线预防治疗的效果比较:实用临床试验的研究方案(PREMI研究)

Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study).
PubMed 文献 · Trials · 2025-08-26

该研究为在西班牙加泰罗尼亚初级保健中开展的IV期、实用、随机、开放、多中心、四平行组临床试验,纳入适合预防治疗的成人偏头痛患者,随机接受普萘洛尔、阿米替林、氟桂利嗪或托吡酯。主要疗效指标为第12周月均偏头痛天数(MMD)较基线的变化,主要非劣效分析在第12周符合方案人群中比较托吡酯与普萘洛尔,阿米替林和氟桂利嗪与普萘洛尔比较为探索性分析。

要点

  • 研究比较普萘洛尔、阿米替林、氟桂利嗪和托吡酯四种常用偏头痛预防药物在初级保健中的效果与安全性。
  • 主要疗效终点为第12周MMD较基线的变化,主要分析为托吡酯对比普萘洛尔的非劣效性。
  • 研究计划评估性别差异及成本效果,并通过专用应用程序让患者积极参与。

核心结论

  • 该研究旨在评估四种常用偏头痛预防药物在减少MMD方面的有效性及安全性,并计划评估其成本效果和性别差异。

研究设计与样本

  • IV期、实用、随机、开放、多中心、四平行组临床试验,在西班牙加泰罗尼亚初级保健中开展。
  • 纳入适合预防治疗的成人偏头痛患者,随机分配至普萘洛尔、阿米替林、氟桂利嗪或托吡酯组。
  • 主要疗效指标为第12周MMD均值较基线MMD均值的变化。
  • 主要非劣效分析在第12周符合方案人群中比较托吡酯与普萘洛尔,阿米替林和氟桂利嗪与普萘洛尔比较为探索性分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Migraine is a neurological disorder affecting approximately 12% of the population, more frequent in women, causing disability. Preventive treatment is recommended to prevent chronification and analgesics' abuse and to improve quality of life, but not all candidates receive it. Common preventive drugs include amitriptyline, flunarizine, propranolol, and topiramate. Their effectiveness and safety have not yet been assessed in our setting. The objective of this study is to evaluate the effectiveness of these drugs in reducing the monthly migraine days (MMD) and to evaluate their safety. METHODS: Phase IV, pragmatic randomized clinical trial of four parallel groups, open and multicentric, in Primary Care in Catalonia, Spain. We will include adults with migraine eligible for preventive treatment. They will be randomized to the following: (1) propranolol, (2) amitriptyline, (3) flunarizine, or (4) topiramate. The main efficacy measure will be the change in the mean MMD at week 12 in comparison to the mean MMD at baseline. Other secondary efficacy and safety measures will be assessed. The main non-inferiority analysis will be conducted in the per protocol population at week 12, comparing topiramate versus propranolol as the main analysis, and amitriptyline and flunarizine versus propranolol as exploratory analyses. DISCUSSION: There are epidemiological, clinical and pharmacological sex-differences in migraine which may result in differences in the use of migraine preventive drugs. However, the effectiveness of the most frequent preventive treatment and the differences in effectiveness and safety between women and men have not yet been studied. Moreover, as new expensive drugs have been authorized for preventive treatment, indicated when the usual drugs have failed, assessing the effectiveness and safety of the usual oral preventive drugs through a clinical trial is especially important. We also plan to evaluate their cost-effectiveness, and the clinical trial will count on an active contribution from patients through an app designed for this purpose, which may help in the management of the disease in the future. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT06499116 ( https://clinicaltrials.gov/study/NCT06499116 ). Trial registration date: July 12, 2024. EU CT Number: 2024-513597-22. Protocol ID: IJG-PREMI-2024. SPONSOR: Fundació d'Investigació en Atenció Primària Jordi Gol i Gurina. Gran Via de les Corts Catalanes 587, àtic. 08007, Barcelona, Spain.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Giner-Soriano M, Morros R, Monfà R, et al. Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study). Trials. 2025. PMID: 40859286. doi:10.1186/s13063-025-08961-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。